PARTICULARS TO APPEAR ON THE OUTER PACKAGE {Cardboard box 20 tablets, 100 tablets}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Rheumocam 1 mg chewable tablets

2. STATEMENT OF ACTIVE SUBSTANCES

Each chewable tablet contains:

Meloxicam 1 mg

3. PACKAGE SIZE

20 chewable tablets
100 chewable tablets

4. TARGET SPECIES

Dogs.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oral use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd.

14. MARKETING AUTHORISATION NUMBERS

Vm 08749/5018

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS {Blister 20 tablets and 100 tablets}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Rheumocam

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Each chewable tablet contains:

Meloxicam 1 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Rheumocam 1 mg chewable tablets for dogs
Rheumocam 2.5 mg chewable tablets for dogs

2. Composition

Each chewable tablet contains:

Active substance:
Meloxicam 1 mg
Meloxicam 2.5 mg

Pale-yellow, single-scored, chewable tablets that can be divided into halves.

3. Target species

Dogs.

4. Indications for use

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.

5. Contraindications

Do not use in pregnant or lactating animals.
Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in dogs less than 6 weeks of age or less than 4 kg body weight.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.

6. Special warnings

Special precautions for safe use in the target species:
This product for dogs should not be used in cats as it is not suitable for use in this species.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.
Pregnancy and lactation:
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. The veterinary medicinal product must not be administered in conjunction with other NSAIDs or glucocorticosteroids.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

Overdose:
In case of overdose, symptomatic treatment should be initiated.

Major incompatibilities:
None known.

7. Adverse events

Dogs:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Appetite loss, Lethargy Vomiting, Diarrhoea, Blood in faeces[1], Haemorrhagic diarrhoea, Haematemesis, Gastric ulcer, Small intestine ulcer, Large intestine ulcer Elevated liver enzymes Renal failure

[1]occult

These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Oral use.

Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day.

Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.
Each chewable tablet contains either 1 mg or 2.5 mg meloxicam, which corresponds to the daily maintenance dose for a 10 kg body weight dog, or a 25 kg body weight dog respectively.
Each chewable tablet can be halved for accurate dosing according to the individual body weight of the animal.
The veterinary medicinal product can be administered with or without food, are flavoured and are taken by most dogs voluntarily.

Dose scheme for the maintenance dose:

Body weight (kg)	Number of chewable tablets		mg/kg
	1 mg	2.5 mg	
4.0–7.0	½		0.13–0.1
7.1–10.0	1		0.14–0.1
10.1–15.0	1½		0.15–0.1
15.1–20.0	2		0.13–0.1
20.1–25.0		1	0.12–0.1
25.1–35.0		1½	0.15–0.1
35.1–50.0		2	0.14–0.1

The use of Rheumocam oral suspension for dogs may be considered for an even more precise dosing. For dogs weighing less than 4 kg the use of Rheumocam oral suspension for dogs is recommended.

A clinical response is normally seen within 3–4 days. Treatment should be discontinued after 10 days if no clinical improvement is apparent.

9. Advice on correct administration

To ensure correct dosage, body weight should be determined as accurately as possible.
The use of suitably calibrated measuring equipment is recommended.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and blister packs after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription**.**

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 08749/5018
Vm 08749/5021

Pack sizes: 20 and 100 tablets.

Not all pack sizes may be marketed.

15. PID link (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse reactions:

Chanelle Pharmaceuticals Manufacturing Ltd
Loughrea
Co Galway
H62 FH90
Ireland.
Tel: +353 91 841788
vetpharmacoviggroup@chanellegroup.ie

17. Other information

POM-V

Gavin Hall
Approved: 16 June 2026